€11.60
0.00% yesterday
Xetra, May 29, 05:36 pm CET
ISIN
DE000A3CMGM5
Symbol
APPH
Index
Sector
Industry

Apontis Pharma Stock price

€11.60
+0.40 3.57% 1M
+1.68 16.94% 6M
+1.55 15.42% YTD
+3.42 41.81% 1Y
-2.00 14.71% 3Y
-7.15 38.13% 5Y
-7.15 38.13% 10Y
Xetra, Closing price Thu, May 29 2025
+0.00 0.00%
ISIN
DE000A3CMGM5
Symbol
APPH
Index
Sector
Industry

Key metrics

Market capitalization €98.60m
Enterprise Value €83.15m
P/E (TTM) P/E ratio 77.33
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.16
P/S ratio (TTM) P/S ratio 1.38
P/B ratio (TTM) P/B ratio 3.12
Revenue growth (TTM) Revenue growth 156.68%
Revenue (TTM) Revenue €71.64m
EBIT (operating result TTM) EBIT €1.77m
Free Cash Flow (TTM) Free Cash Flow €-5.87m
Cash position €15.45m
EPS (TTM) EPS €0.15
P/E forward 36.25
P/S forward 1.80
EV/Sales forward 1.51
Show more

Is Apontis Pharma a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Apontis Pharma Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Apontis Pharma:

1x Sell
100%

Analyst Opinions

1 Analyst has issued a forecast Apontis Pharma:

Sell
100%

Financial data from Apontis Pharma

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
72 72
157% 157%
100%
- Direct Costs 30 30
194% 194%
42%
41 41
135% 135%
58%
- Selling and Administrative Expenses 21 21
5% 5%
29%
- Research and Development Expense - -
-
-
5.15 5.15
148% 148%
7%
- Depreciation and Amortization 3.38 3.38
135% 135%
5%
EBIT (Operating Income) EBIT 1.77 1.77
115% 115%
2%
Net Profit 1.25 1.25
113% 113%
2%

In millions EUR.

Don't miss a Thing! We will send you all news about Apontis Pharma directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. Its single pill products focus on cardiovascular diseases such as hypertension, hyperlipidemia, and secondary prevention. The company was founded on March 19, 2018 and is headquartered in Monheim am Rhein, Germany.

Head office Germany
CEO Bruno Wohlschlegel
Employees 177
Founded 2018
Website www.apontis-pharma.de

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today